Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of acoramidis in symptomatic transthyretin amyloid cardiomyopathy after completion of ATTRibute-CM
MOH_2022-01-26_010287Phase 3Active, not recruiting
- Sponsor
- Eidos Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Eidos Therapeutics. Primary endpoint: Long-term safety and tolerability of acoramidis. Started Dec 2021; status: active, not recruiting.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on MOH_2022-01-26_010287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-26_010287.